Cancer Biomarkers: Adoption Is Driving Growth

Chapter - 1

• BACKGROUND
• 1.1. Cancer Staging
• 1.2. AACR/FDA/NCI Collaborative
• 1.3. Cancer Biomarkers
• 1.4. Genetics
• 1.5. Research Areas
• 1.6. Treatment Selection
• 1.7. New Biomarkers
• 1.8. Circulating Tumor Cells
• 1.9. Cancer Stem Cells
• 1.10. Classification

Chapter - 2

• THE DISCOVERY OF CANCER BIOMARKERS
• 2.1. Genetic Methods
  • DNA Arrays
  • Southern Blot
  • Polymerase Chain Reaction (PCR)
  • Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
  • Fluorescent In Situ Hybridization (FISH)
• 2.2. Protein Methods
  • Immunohistochemistry
  • Mass Spectrometry
• 2.3. Metabolomics
• 2.4. Imaging
  • Imaging Techniques
  • Positron Emission Tomography (PET)
  • Computed Tomography (CT)
  • Magnetic Resonance Spectroscopy (MRS)
  • Magnetic Resonance Imaging (MRI)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Ultrasound
  • X-ray
  • Biophotonics

Chapter - 3

• IMPORTANT CANCER BIOMARKERS
• 3.1. Lung Cancer
  • Proteins
  • Genes and Gene Arrays
  • Splice Variants (Ciz1)
  • Serum L-Lactate Dehydrogenase
  • Telomerase
• 3.2. Colorectal Cancer
  • Early Detection
  • Proteins by SELDI
  • Fecal DNA
  • Genes and Epigenetic Markers
  • Carcinoembryonic Antigen
• 3.3. Prostate Cancer
  • Prostate-Specific Antigen (PSA)
  • TIMP1
  • MUC1
  • B7-H3
  • Genetic Biomarkers
  • Epigenetic Alterations
• 3.4. Breast Cancer
  • Growth Factors and Receptors
  • Genetic Markers
  • 3.5. Ovarian Cancer
  • CA125
  • Lysophospholipids
  • H4
  • Mammaglobin-2
• 3.6. Pancreatic Cancer
  • CA19-9
  • Blood Proteins
  • MUC1
• 3.7. Liver Cancer
• 3.8. Leukemia
• 3.9. Other Cancers
• 3.10. Outlook for the Use of Cancer Biomarkers

Chapter - 4

• COMMERCIAL MARKETS
• 4.1. Commercial Importance of Biomarkers
  • Competitive Opportunities
  • Cost Saving
• 4.2. Market Considerations
  • Economic Importance
  • Companies

Chapter - 5

• SWOT ANALYSIS
• 5.1. Strengths
  • Patients
  • Healthcare Payers/Reimbursers
  • Healthcare Providers
  • Diagnostic/Drug Development Companies
• 5.2. Weaknesses
• 5.3. Opportunities
  • Patients
  • Healthcare Payers/Reimbursers
  • Healthcare Providers
  • Diagnostic/Drug Development Companies
• 5.4. Threats

Chapter - 6

• INSIGHT PHARMA REPORTS CANCER BIOMARKERS SURVEY- FEBRUARY 2008

Chapter - 7

• INTERVIEWS WITH CANCER BIOMARKER EXPERTS
• 7.1. Mark Reynolds, PhD; Senior Director, Gen-Probe
• 7.2. Mark Chandler, PhD; Chairman and CEO, Biophysical Corporation
• 7.3. Roberto Hernan, PhD; Head of Business Development, Dominion Pharmakine
• 7.4. Michael Milburn, PhD; Chief Scientific Officer, Metabolon

Chapter - 8

• DISCUSSION AND SUMMARY OF CANCER BIOMARKER FINDINGS
• 8.1. Background
• 8.2. Studying Cancer Biomarkers
• 8.3. Important Cancer Biomarkers
• 8.4. Cancers
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancers
• 8.5. Markets

References

Company Index with Web Addresses

• Table 1.1. Current and Potential Applications of Breast Cancer Biomarkers
• Table 1.2. Examples of the Functional Classification of Cancer Biomarkers
• Table 3.1. Lung Cancer Biomarkers
• Table 3.2. Colorectal Cancer Biomarkers
• Table 3.3. Prostate Cancer Biomarkers
• Table 3.4. Breast Cancer Biomarkers
• Table 3.5. Ovarian Cancer Biomarkers
• Table 3.6. Pancreatic Cancer Biomarkers
• Table 3.7. Liver Cancer Biomarkers
• Table 3.8. Other Cancer Biomarkers
• Table 3.9. Current and Potential Applications of Cancer Biomarkers
• Table 4.1. Organizations Involved in the Development and/or Commercialization of Cancer Biomarkers
• Table 4.2. Prominent Organizations Involved in the Study and/or Commercialization of Cancer Biomarkers

• Figure 1.1. Breast Cancer Biomarker Profile
• Figure 3.1. Classification of Cancer Biomarkers by Type
• Figure 3.2. Classification of Cancer Biomarkers by Cancer
• Figure 4.1. Biomarker Patent Filings According to Indication
• Figure 4.2. Biomarker Patent Filings According to Cancer Type
• Figure 6.1. Respondents by Sector
• Figure 6.2. Respondents by Position
• Figure 6.3. Respondents by Stage of Work
• Figure 6.4. Respondents by Area of Work
• Figure 6.5. Types of Cancer Biomarkers Studied
• Figure 6.6. Views on Collaborative Biomarker Development
• Figure 6.7. Experience with Novel Cancer Biomarkers
• Figure 6.8. Means by Which Cancer Biomarker Discovery or Development Is Done
• Figure 6.9. Technologies Used to Discover Cancer Biomarkers
• Figure 6.10. Focus of Biomarker Work
• Figure 6.11. Types of Organizations Involved with Cancer Diagnostics/Biomarker Development
• Figure 6.12. Reasons for Organizations' Lack of Involvement with Cancer Biomarkers
• Figure 6.13. 2008 Budget for Cancer Biomarkers
• Figure 6.14. Areas of Cancer Biomarker Development